Molecular, cellular and clinical impact of ALCAM (CD166) and its molecular complex in the skeletal metastasis of endocrine related cancers

Yang, Yiming 2022. Molecular, cellular and clinical impact of ALCAM (CD166) and its molecular complex in the skeletal metastasis of endocrine related cancers. MD Thesis, Cardiff University. Item availability restricted.

Preview	PDF - Accepted Post-Print Version Download (13MB) | Preview
	PDF (Cardiff University Electronic Publication Form) - Supplemental Material Restricted to Repository staff only Download (133kB)

Abstract

Activated leukocyte cell adhesion molecule (ALCAM/CD166) belongs to the immunoglobulin superfamily of cell adhesion molecules. It has demonstrated that ALCAM regulates cell adhesion and migration in multiple cancer types and is strongly correlated with the clinical outcome of patients with cancers, especially breast cancer. The present study examined the clinical implication of ALCAM in endocrine-related cancers (breast cancer and pituitary tumour). We also explored the role of ALCAM in a non-endocrine related cancer, pancreatic cancer, to further establish the relationship between ALCAM and endocrine tumours. The results showed that ALCAM acted as an inhibitory factor to bone metastasis and was shown to be a positive prognostic factor of survival in breast cancer. The relationships between ALCAM and the clinical course of the patients were contrasted between endocrine related and non-endocrine related cancers. The study also explored the effect of ALCAM on different subtypes of breast cancer cell lines and the signalling events underlying ALCAM and their involvement in hormonal receptor related bone metastasis. The results showed that ALCAM exerted different biological effects on breast cancer cell lines with different ER statusesin both normal and mimicked bone microenvironments. MET was found to be a vital signalling molecule in the context of ALCAM actions in these cancer cells. In addition, ALCAM wasfound to be able to influence the sensitivity of chemotherapy drugs in certain breast cancer cell lines and this influence was hormone receptor dependent. The study concludes that ALCAM is a vital factor in cancer progression including bone metastasis of breast cancer and assessing the prognosis of the patients, a connection contrasted to non-endocrine pancreatic cancer. The biological actions of ALCAM on breast cancer cells are hormone receptor dependent with MET protooncogene playing a key role.

Item Type:	Thesis (MD)
Date Type:	Completion
Status:	Unpublished
Schools:	Medicine
Date of First Compliant Deposit:	11 October 2022
Last Modified:	11 Oct 2023 01:30
URI:	https://orca.cardiff.ac.uk/id/eprint/153294

Actions (repository staff only)

Edit Item